148 related articles for article (PubMed ID: 19236136)
1. Containing costs and containing bugs: are they mutually exclusive?
Nicolau DP
J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S12-7. PubMed ID: 19236136
[TBL] [Abstract][Full Text] [Related]
2. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.
Kuti JL; Capitano B; Nicolau DP
Pharmacoeconomics; 2002; 20(8):513-28. PubMed ID: 12109917
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
Friedman H; Song X; Crespi S; Navaratnam P
Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
[TBL] [Abstract][Full Text] [Related]
4. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
File TM
J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
[TBL] [Abstract][Full Text] [Related]
5. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
Dresser LD; Niederman MS; Paladino JA
Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
[TBL] [Abstract][Full Text] [Related]
7. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
[TBL] [Abstract][Full Text] [Related]
8. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
9. A clinical pathway for community-acquired pneumonia: an observational cohort study.
Frei CR; Bell AM; Traugott KA; Jaso TC; Daniels KR; Mortensen EM; Restrepo MI; Oramasionwu CU; Ruiz AD; Mylchreest WR; Sikirica V; Raut MR; Fisher A; Schein JR
BMC Infect Dis; 2011 Jul; 11():188. PubMed ID: 21733161
[TBL] [Abstract][Full Text] [Related]
10. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Drummond MF; Becker DL; Hux M; Chancellor JV; Duprat-Lomon I; Kubin R; Sagnier PP
Chest; 2003 Aug; 124(2):526-35. PubMed ID: 12907538
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Martin M; Moore L; Quilici S; Decramer M; Simoens S
Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
[TBL] [Abstract][Full Text] [Related]
12. The healthcare costs of antimicrobial resistance in Lebanon: a multi-centre prospective cohort study from the payer perspective.
Iskandar K; Roques C; Hallit S; Husni-Samaha R; Dirani N; Rizk R; Abdo R; Yared Y; Matta M; Mostafa I; Matta R; Salameh P; Molinier L
BMC Infect Dis; 2021 May; 21(1):404. PubMed ID: 33933013
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
[TBL] [Abstract][Full Text] [Related]
14. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of america guidelines.
Orrick JJ; Segal R; Johns TE; Russell W; Wang F; Yin DD
Pharmacoeconomics; 2004; 22(11):751-7. PubMed ID: 15250752
[TBL] [Abstract][Full Text] [Related]
15. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
Samsa GP; Matchar DB; Harnett J; Wilson J
Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
[TBL] [Abstract][Full Text] [Related]
16. Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia.
Cortoos PJ; Gilissen C; Laekeman G; Peetermans WE; Leenaers H; Vandorpe L; Simoens S
Scand J Infect Dis; 2013 Mar; 45(3):219-26. PubMed ID: 23113827
[TBL] [Abstract][Full Text] [Related]
17. Approaches to drug therapy, formulary, and pathway management in a large community hospital.
Halley HJ
Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S17-21. PubMed ID: 11098316
[TBL] [Abstract][Full Text] [Related]
18. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies.
Owens RC; Shorr AF
Am J Health Syst Pharm; 2009 Jun; 66(12 Suppl 4):S23-30. PubMed ID: 19502225
[TBL] [Abstract][Full Text] [Related]
19. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F
Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia.
Smith KJ; Wateska A; Nowalk MP; Raymund M; Lee BY; Zimmerman RK; Fine MJ
J Gen Intern Med; 2013 Sep; 28(9):1157-64. PubMed ID: 23463457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
